MERIDIAN: A 12-month prospective, open-label, randomized, multicenter, parallel-group study to evaluate the efficacy, safety and tolerability of a Myfortic-based regimen in the conversion from a CNI to everolimus in de novo transplant recipients of Expanded Criteria of Donor kidneys

Trial Profile

MERIDIAN: A 12-month prospective, open-label, randomized, multicenter, parallel-group study to evaluate the efficacy, safety and tolerability of a Myfortic-based regimen in the conversion from a CNI to everolimus in de novo transplant recipients of Expanded Criteria of Donor kidneys

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 12 Apr 2016

At a glance

  • Drugs Everolimus (Primary) ; Ciclosporin
  • Indications Renal transplant rejection
  • Focus Adverse reactions
  • Acronyms MERIDIAN
  • Sponsors Novartis Pharma A.G.
  • Most Recent Events

    • 10 Apr 2016 Status changed from recruiting to discontinued, as reported by European Clinical Trials Database record.
    • 21 Jun 2011 This study is currently recruiting in Spain, but has been prematurely discontinued in Latvia (15 Jun 2010) and the Czech Republic (6 Jul 2010).
    • 21 Jun 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top